Keynote Session: Experience With Innovative Therapies
A Focus on CAR T-Cell Therapy
The use of innovative treatments such as chimeric antigen receptor (CAR) T-cell therapy is rapidly expanding. The challenges of receiving and delivering this novel therapy were discussed at the NCCN 2019 Annual Conference’s keynote session. In a separate roundtable discussion, additional stakeholders discussed how payers and providers are grappling with the cost of incorporating CAR T-cell therapy into practices.
© 2019-2024 National Comprehensive Cancer Network